70
Participants
Start Date
February 2, 2022
Primary Completion Date
February 15, 2026
Study Completion Date
February 15, 2027
TORL-2-307-ADC
antibody drug conjugate
RECRUITING
Seoul National University Bundang Hospital, Seoul
RECRUITING
Fort Wayne Medical Oncology and Hematology, Fort Wayne
RECRUITING
Washington University School of Medicine-Siteman Cancer Center, St Louis
RECRUITING
Texas Oncology-Dallas, Dallas
RECRUITING
Texas Oncology-Tyler, Tyler
RECRUITING
START San Antonio, San Antonio
RECRUITING
Texas Oncology-Austin, Austin
RECRUITING
UCLA - JCCC Clinical Research Unit, Los Angeles
RECRUITING
Torrance Memorial Medical, Torrance
RECRUITING
Providence St. Jude Medical Center, Fullerton
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital, Yonsei University Health System, Seoul
Translational Research in Oncology
OTHER
TORL Biotherapeutics, LLC
INDUSTRY